TY - JOUR
T1 - Randomized controlled trial to evaluate radiotherapy ± endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy
T2 - Japan Clinical Oncology Group Study JCOG 0401
AU - Yokomizo, Akira
AU - Kawamoto, Hiroshi
AU - Nihei, Keiji
AU - Ishizuka, Naoki
AU - Kakehi, Yoshiyuki
AU - Tobisu, Ken Ichi
AU - Naito, Seiji
N1 - Funding Information:
The study was supported by Health Sciences Research Grants for Clinical Research for Evidenced Based Medicine and Grants-in-Aid for Cancer Research (14S-4), from the Ministry of Health, Labor and Welfare, Japan.
PY - 2005
Y1 - 2005
N2 - A randomized controlled trial has started in Japan to evaluate radiotherapy and endocrine therapy for prostate-specific antigen (PSA) failure after radical prostatectomy. Patients who have PSA failure after radical prostatectomy for localized prostate cancer (T1-2N0M0) are randomized into treatment groups of either radiotherapy ± endocrine therapy or endocrine therapy alone. The Urologic Oncology Study Group (UOSG) in the Japan Clinical Oncology Group (JCOG) composed of 36 specialized institutions will recruit 200 patients. The primary end-point is time to treatment failure (TTF) of bicalutamide, and secondary end-points are TTF of protocol treatment, progression-free survival, overall survival, adverse events and quality of life (QOL). The Clinical Trial Review Committee of the JCOG approved the protocol on April 13, 2004, and the study was activated on May 17, 2004.
AB - A randomized controlled trial has started in Japan to evaluate radiotherapy and endocrine therapy for prostate-specific antigen (PSA) failure after radical prostatectomy. Patients who have PSA failure after radical prostatectomy for localized prostate cancer (T1-2N0M0) are randomized into treatment groups of either radiotherapy ± endocrine therapy or endocrine therapy alone. The Urologic Oncology Study Group (UOSG) in the Japan Clinical Oncology Group (JCOG) composed of 36 specialized institutions will recruit 200 patients. The primary end-point is time to treatment failure (TTF) of bicalutamide, and secondary end-points are TTF of protocol treatment, progression-free survival, overall survival, adverse events and quality of life (QOL). The Clinical Trial Review Committee of the JCOG approved the protocol on April 13, 2004, and the study was activated on May 17, 2004.
UR - http://www.scopus.com/inward/record.url?scp=14944374004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14944374004&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyi007
DO - 10.1093/jjco/hyi007
M3 - Article
C2 - 15681602
AN - SCOPUS:14944374004
SN - 0368-2811
VL - 35
SP - 34
EP - 36
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 1
ER -
